JP2016536020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536020A5 JP2016536020A5 JP2016552471A JP2016552471A JP2016536020A5 JP 2016536020 A5 JP2016536020 A5 JP 2016536020A5 JP 2016552471 A JP2016552471 A JP 2016552471A JP 2016552471 A JP2016552471 A JP 2016552471A JP 2016536020 A5 JP2016536020 A5 JP 2016536020A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- set forth
- variable region
- chain variable
- region set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims 24
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 24
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 6
- 206010014733 Endometrial cancer Diseases 0.000 claims 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical group C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 4
- 102100038449 Claudin-6 Human genes 0.000 claims 3
- 101000882898 Homo sapiens Claudin-6 Proteins 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102000002029 Claudin Human genes 0.000 claims 2
- 108050009302 Claudin Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 108010044540 auristatin Proteins 0.000 claims 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 2
- 229930195731 calicheamicin Natural products 0.000 claims 2
- 210000004907 gland Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 102100026097 Claudin-9 Human genes 0.000 claims 1
- 101000912661 Homo sapiens Claudin-9 Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000000562 conjugate Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000005102 tumor initiating cell Anatomy 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000013598 vector Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900916P | 2013-11-06 | 2013-11-06 | |
| US61/900,916 | 2013-11-06 | ||
| PCT/US2014/064165 WO2015069794A2 (en) | 2013-11-06 | 2014-11-05 | Novel anti-claudin antibodies and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016536020A JP2016536020A (ja) | 2016-11-24 |
| JP2016536020A5 true JP2016536020A5 (https=) | 2017-08-10 |
| JP6515111B2 JP6515111B2 (ja) | 2019-05-22 |
Family
ID=53042314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552471A Expired - Fee Related JP6515111B2 (ja) | 2013-11-06 | 2014-11-05 | 新規の抗クローディン抗体および使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10053511B2 (https=) |
| EP (1) | EP3065776A4 (https=) |
| JP (1) | JP6515111B2 (https=) |
| KR (1) | KR20160070191A (https=) |
| CN (1) | CN105813650A (https=) |
| AR (1) | AR102554A1 (https=) |
| AU (1) | AU2014346792A1 (https=) |
| BR (1) | BR112016010169A2 (https=) |
| CA (1) | CA2928671A1 (https=) |
| CL (1) | CL2016001102A1 (https=) |
| IL (1) | IL245237A0 (https=) |
| MX (1) | MX2016005763A (https=) |
| PE (1) | PE20160870A1 (https=) |
| PH (1) | PH12016500781A1 (https=) |
| RU (1) | RU2016122041A (https=) |
| SG (1) | SG11201603397QA (https=) |
| WO (1) | WO2015069794A2 (https=) |
| ZA (1) | ZA201603308B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS67768B1 (sr) | 2010-11-30 | 2026-03-31 | Chugai Pharmaceutical Co Ltd | Terapijski agens koji indukuje citotoksičnost |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| PE20160870A1 (es) * | 2013-11-06 | 2016-09-09 | Abbvie Stemcentrx Llc | Anticuerpos anti-claudina novedosos y metodos de uso |
| TWI712421B (zh) | 2013-11-11 | 2020-12-11 | 日商中外製藥股份有限公司 | 含改變的抗體可變區之抗原結合分子 |
| MA40921A (fr) * | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |
| TWI880146B (zh) | 2014-11-11 | 2025-04-11 | 日商中外製藥股份有限公司 | 包含經改變之抗體可變區之抗原結合分子的資料庫 |
| PE20181302A1 (es) * | 2015-12-04 | 2018-08-09 | Abbvie Stemcentrx Llc | Nuevos anticuerpos anti-claudina y sus metodos de uso |
| IL299099B2 (en) | 2016-06-27 | 2025-07-01 | Univ California | Cancer treatment combinations |
| CA3049727C (en) * | 2017-01-13 | 2022-10-04 | Vasomune Therapeutics Inc. | An agent for promoting angiogenesis and methods and uses thereof |
| IL273196B2 (en) * | 2017-09-18 | 2024-11-01 | Univ California | Claudin6 antibodies and methods of treating cancer |
| IL301637B2 (en) * | 2017-09-29 | 2024-10-01 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| TW201938194A (zh) | 2017-12-05 | 2019-10-01 | 日商中外製藥股份有限公司 | 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子 |
| KR102340989B1 (ko) | 2018-03-28 | 2021-12-20 | 에이비온 주식회사 | 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도 |
| US12134645B2 (en) | 2018-08-21 | 2024-11-05 | Albert Einstein College Of Medicine | Monoclonal antibodies against human tim-3 |
| EP3924389A4 (en) | 2019-02-15 | 2023-06-14 | Integral Molecular, Inc. | CLAUDIN-6 ANTIBODIES AND THEIR USES |
| AU2020241896A1 (en) | 2019-03-20 | 2021-09-23 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
| EP3950061A4 (en) | 2019-03-25 | 2022-11-16 | Daiichi Sankyo Company, Limited | ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE |
| CN117659190A (zh) * | 2019-05-16 | 2024-03-08 | 启愈生物技术(上海)有限公司 | 抗cldn抗体及其药物组合物和检测方法 |
| WO2020237088A1 (en) * | 2019-05-21 | 2020-11-26 | University Of Miami | Treatment of sensorineural deafness |
| CR20220049A (es) | 2019-07-10 | 2022-03-02 | Chugai Pharmaceutical Co Ltd | Moléculas de unión a claudina-6 y usos de las mismas |
| JP7597784B2 (ja) | 2019-07-11 | 2024-12-10 | タヴォテック バイオセラピューティクス （ホン コン） リミテッド | 胸腺間質性リンパ球新生因子（ｔｓｌｐ）受容体シグナル伝達に干渉する薬剤 |
| KR20210037581A (ko) * | 2019-09-26 | 2021-04-06 | (재)록원바이오융합연구재단 | 항-클라우딘-3 키메라 항원 수용체 |
| CA3174094A1 (en) | 2020-03-31 | 2021-10-07 | Shinya Ishii | Claudin-6 targeting multispecific antigen-binding molecules and uses thereof |
| CA3212530A1 (en) * | 2021-03-05 | 2022-09-09 | Shanghai GenBase Biotechnology Co., Ltd. | Anti-cldn6 antibody and use thereof |
| WO2022268200A1 (zh) * | 2021-06-25 | 2022-12-29 | 信达生物制药(苏州)有限公司 | 针对密蛋白18.2的抗体及其用途 |
| KR102451185B1 (ko) * | 2021-08-05 | 2022-10-07 | 환인제약 주식회사 | 도네페질 함유 지속방출형 미립구 |
| JPWO2023053282A1 (https=) | 2021-09-29 | 2023-04-06 | ||
| EP4626933A1 (en) | 2022-11-30 | 2025-10-08 | Integral Molecular, Inc. | Antibodies directed to claudin 6, including bispecific formats thereof |
| CN121175338A (zh) * | 2023-04-30 | 2025-12-19 | 泰诚思生物医药私人有限公司 | hCLDN6的抗原结合蛋白和其用途 |
| US12403202B2 (en) | 2023-05-25 | 2025-09-02 | The Regents Of The University Of California | Dosage of claudin-6 conjugates for cancer treatment |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5191066A (en) | 1990-12-07 | 1993-03-02 | Abbott Laboratories | Site-specific conjugation of immunoglobulins and detectable labels |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| US20020192209A1 (en) | 1997-09-17 | 2002-12-19 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| AU2559799A (en) | 1998-01-22 | 1999-08-09 | Genentech Inc. | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same |
| DE69930328T2 (de) | 1998-08-27 | 2006-12-14 | Spirogen Ltd., Ryde | Dimere Pyrrolobenzodiazepine |
| US6756356B2 (en) | 1998-11-03 | 2004-06-29 | Adherex Technologies, Inc. | Compounds and methods for modulating claudin-mediated functions |
| US7026449B2 (en) | 1999-01-05 | 2006-04-11 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
| WO2003088808A2 (en) | 2002-04-16 | 2003-10-30 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| EP1419786A1 (en) | 2002-11-13 | 2004-05-19 | Bracco Imaging S.p.A. | Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| DK1633784T3 (da) | 2003-05-09 | 2011-10-24 | Diadexus Inc | OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| AU2004273791A1 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| SI2270010T1 (sl) | 2004-03-01 | 2012-05-31 | Spirogen Ltd | hidroksi H pirolo c benzodiazepin onski derivati kot ključni intermediati za pripravo C substituiranih pirolobenzodiazepinov |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
| US7189710B2 (en) | 2004-03-30 | 2007-03-13 | Council Of Scientific And Industrial Research | C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers |
| FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| SI1813614T1 (sl) | 2006-01-25 | 2012-01-31 | Sanofi 174 | Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate |
| ES2567402T3 (es) | 2006-05-30 | 2016-04-22 | Genentech, Inc. | Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos |
| EP2032694A4 (en) | 2006-06-06 | 2010-09-15 | Univ Tennessee Res Foundation | COMPOSITIONS ENRICHED WITH NEOPLASTIC STEM CELLS AND THESE COMPREHENSIVE METHODS |
| US20080220448A1 (en) | 2006-09-01 | 2008-09-11 | Blincko Stuart J | Antigenic protein conjugates and process for preparing same |
| ES2646545T3 (es) | 2006-09-07 | 2017-12-14 | Arthur E. Frankel | Métodos y composiciones basadas en conjugados de toxina diftérica-interleucina-3 |
| US7825267B2 (en) | 2006-09-08 | 2010-11-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of FR901464 and analogs with antitumor activity |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| KR101523698B1 (ko) | 2007-01-22 | 2015-05-29 | 마크로제닉스 웨스트 인코퍼레이티드 | 사람 암 줄기세포 |
| WO2008114733A1 (ja) | 2007-03-16 | 2008-09-25 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-4抗体 |
| EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| MX2010002683A (es) | 2007-09-14 | 2010-03-26 | Amgen Inc | Poblaciones de anticuerpos homogeneos. |
| CN101918450A (zh) * | 2008-01-11 | 2010-12-15 | 国立大学法人东京大学 | 抗cldn6抗体 |
| JP2011509675A (ja) * | 2008-01-18 | 2011-03-31 | メディミューン，エルエルシー | 部位特異的コンジュゲーションのためのシステイン操作抗体 |
| US20100162416A1 (en) | 2008-09-29 | 2010-06-24 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| LT2398902T (lt) | 2009-02-20 | 2023-12-27 | Astellas Pharma Inc. | Vėžio diagnostikos ir gydymo būdai bei kompozicijos |
| TWI682995B (zh) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
| US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| NZ716587A (en) | 2009-11-11 | 2017-10-27 | Ganymed Pharmaceuticals Ag | Antibodies specific for claudin 6 (cldn6) |
| AU2011213609B2 (en) * | 2010-02-08 | 2016-11-03 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 161P2F10B proteins |
| CA2790401C (en) | 2010-02-21 | 2018-05-29 | Bayer Healthcare Llc | Method for activation and conjugation of biomolecules |
| JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
| US8697688B2 (en) | 2010-04-15 | 2014-04-15 | Seattle Genetics Inc. | Pyrrolobenzodiazepines used to treat proliferative diseases |
| MX391454B (es) | 2010-04-15 | 2025-03-05 | Seagen Inc | Compuesto de engarce-fármaco para conjugación a una unidad de ligando. |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| BR112012030311A2 (pt) | 2010-06-08 | 2017-01-24 | Genentech Inc | anticorpo |
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| EP2611463A2 (en) | 2010-09-03 | 2013-07-10 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| WO2012064733A2 (en) | 2010-11-09 | 2012-05-18 | Medimmune, Llc | Antibody scaffold for homogenous conjugation |
| WO2012078761A2 (en) | 2010-12-09 | 2012-06-14 | Bayer Healthcare Llc | Dimeric molecular complexes with free cysteine residues and conjugates thereof |
| RS56793B1 (sr) | 2011-03-02 | 2018-04-30 | Roche Glycart Ag | Cea antitela |
| US9321842B2 (en) * | 2011-05-13 | 2016-04-26 | Ganymed Pharmaceuticals Ag | Antibodies for treatment of cancer |
| LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| US9714291B2 (en) | 2012-10-05 | 2017-07-25 | Kyowa Hakko Kirin Co., Ltd | Heterodimer protein composition |
| CN104837502B (zh) | 2012-10-12 | 2018-08-10 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
| WO2014075788A1 (en) | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| WO2014075697A1 (en) | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| KR102447350B1 (ko) | 2013-02-08 | 2022-09-23 | 노파르티스 아게 | 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위 |
| EP3470513B1 (en) | 2013-03-15 | 2020-05-13 | Expression Pathology, Inc. | Srm assay to indicate cancer therapy |
| US9517276B2 (en) | 2013-06-04 | 2016-12-13 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
| WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| AU2014312215B2 (en) | 2013-08-28 | 2020-02-27 | Abbvie Stemcentrx Llc | Site-specific antibody conjugation methods and compositions |
| PE20160870A1 (es) * | 2013-11-06 | 2016-09-09 | Abbvie Stemcentrx Llc | Anticuerpos anti-claudina novedosos y metodos de uso |
| KR20230088389A (ko) | 2014-02-11 | 2023-06-19 | 씨젠 인크. | 단백질의 선택적 환원 |
| SI3126381T2 (sl) | 2014-04-01 | 2022-05-31 | Biontech Cell&Gene Therapies Gmbh | Claudin-6-specifični imunoreceptorji in t-celični epitopi |
| EP3209334A2 (en) | 2014-10-20 | 2017-08-30 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
| MA40921A (fr) * | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |
-
2014
- 2014-11-05 PE PE2016000592A patent/PE20160870A1/es unknown
- 2014-11-05 SG SG11201603397QA patent/SG11201603397QA/en unknown
- 2014-11-05 MX MX2016005763A patent/MX2016005763A/es unknown
- 2014-11-05 CN CN201480068471.4A patent/CN105813650A/zh active Pending
- 2014-11-05 CA CA2928671A patent/CA2928671A1/en not_active Abandoned
- 2014-11-05 KR KR1020167015010A patent/KR20160070191A/ko not_active Withdrawn
- 2014-11-05 US US15/034,992 patent/US10053511B2/en active Active
- 2014-11-05 JP JP2016552471A patent/JP6515111B2/ja not_active Expired - Fee Related
- 2014-11-05 WO PCT/US2014/064165 patent/WO2015069794A2/en not_active Ceased
- 2014-11-05 RU RU2016122041A patent/RU2016122041A/ru not_active Application Discontinuation
- 2014-11-05 AU AU2014346792A patent/AU2014346792A1/en not_active Abandoned
- 2014-11-05 BR BR112016010169A patent/BR112016010169A2/pt not_active Application Discontinuation
- 2014-11-05 EP EP14860725.2A patent/EP3065776A4/en not_active Withdrawn
-
2015
- 2015-11-05 AR ARP150103600A patent/AR102554A1/es unknown
-
2016
- 2016-04-20 IL IL245237A patent/IL245237A0/en unknown
- 2016-04-27 PH PH12016500781A patent/PH12016500781A1/en unknown
- 2016-05-06 CL CL2016001102A patent/CL2016001102A1/es unknown
- 2016-05-16 ZA ZA201603308A patent/ZA201603308B/en unknown
-
2018
- 2018-08-20 US US16/105,651 patent/US20190077876A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016536020A5 (https=) | ||
| JP2016531915A5 (https=) | ||
| CN111148761B (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2017500028A5 (https=) | ||
| JP2016538318A5 (https=) | ||
| JP2015509947A5 (https=) | ||
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JP2019532056A5 (https=) | ||
| HRP20240924T1 (hr) | Anti - sirpalpha antitijela | |
| JP2017535246A5 (https=) | ||
| JP2016531914A5 (https=) | ||
| JP2017534256A5 (https=) | ||
| CN111110862A (zh) | 抗cldn18．2抗体的药物偶联体及其制备方法和用途 | |
| JP2015509948A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2016503067A5 (https=) | ||
| CA3146341A1 (en) | Bispecific anti lrrc15 and cd3epsilun antibudies | |
| JP2017535257A5 (https=) | ||
| JP2017518040A5 (https=) | ||
| HRP20202047T1 (hr) | Antitijelo za igf-1r i njegova upotreba kao usmjeravajućeg vezikula za liječenje karcinoma | |
| JP2015509938A5 (https=) | ||
| HRP20191169T1 (hr) | Konjugati antidll3-protutijelo-pbd i njihove uporabe | |
| JP2016505546A5 (https=) | ||
| CN116948035A (zh) | 多特异性抗体及其制备和使用方法 | |
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) |